DUBLIN--(BUSINESS WIRE)--The "Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period.
Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.
Based on end user, the plasma fractionation market is segmented into hospitals and clinics, clinical research laboratories, and academic institutes. In 2019, the hospitals and clinics segment accounted for the largest share of the global plasma fractionation market. The large share of this segment is attributed to the increasing adoption of plasma products in the treatment of various diseases, large patient pool treated in hospitals, and the increasing number of hospitals and clinics across the globe.
The pulmonology application segment will witness the highest growth in the plasma fractionation market.
Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2019, the pulmonology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven largely by the rising prevalence of alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease (copd).
North America will dominate the market during the forecast period.
Geographically, the plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the growing use of immunoglobulins in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD.
Market Dynamics
Drivers
- Growing Use of Immunoglobulins in Various Therapeutic Areas
- Rising Geriatric Population
- Growing Prevalence of Respiratory Diseases and AATD
Restraints
- High Cost and Limited Reimbursement
- Emergence of Recombinant Alternatives
Opportunities
- Increased Risk of Pandemics and Communicable Diseases
- Rising Prevalence of Bleeding Disorders
Challenges
- Stringent Government Regulations
Company Profiles
- CSL
- Grifols
- Shire
- Octapharma
- Kedrion
- LFB
- Biotest
- Sanquin
- China Biologic Products
- Bio Products Laboratory
- Japan Blood Products Organization
- Gc Pharma
- Shanghai Raas Blood Products
- Emergent Biosolutions
- Intas Biopharmaceuticals
- Bharat Serums and Vaccines Limited
- Sk Plasma
- Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
- Kabafusion
- Centurion Pharma
For more information about this report visit https://www.researchandmarkets.com/r/t2r9f7
